Pharmacokinetics of Rifampin and Cyclo-Pentyl Rifampin (Rifapentine) in Elephant and Man

MISSING IMAGE

Material Information

Title:
Pharmacokinetics of Rifampin and Cyclo-Pentyl Rifampin (Rifapentine) in Elephant and Man
Physical Description:
1 online resource (102 p.)
Language:
english
Creator:
Egelund, Eric Free
Publisher:
University of Florida
Place of Publication:
Gainesville, Fla.
Publication Date:

Thesis/Dissertation Information

Degree:
Doctorate ( Ph.D.)
Degree Grantor:
University of Florida
Degree Disciplines:
Pharmaceutical Sciences, Pharmacotherapy and Translational Research
Committee Chair:
PELOQUIN,CHARLES A
Committee Co-Chair:
PALMIERI,ANTHONY,III
Committee Members:
FRYE,REGINALD F
LAUZARDO,MICHAEL

Subjects

Subjects / Keywords:
elephant -- human -- rifampin -- rifapentine -- tuberculosis
Pharmacotherapy and Translational Research -- Dissertations, Academic -- UF
Genre:
Pharmaceutical Sciences thesis, Ph.D.
bibliography   ( marcgt )
theses   ( marcgt )
government publication (state, provincial, terriorial, dependent)   ( marcgt )
born-digital   ( sobekcm )
Electronic Thesis or Dissertation

Notes

Abstract:
The rifamycins have been an integral part of tuberculosis treatment since the approval of rifampin by the Food and Drug Administration in 1971. The inclusion of rifampin as part of the tuberculosis treatment regimen reduced the treatment period from 18 to 9 months. Due to its potent sterilizing effect against Mycobacterium tuberculosis and sound safety profile, future regimens will likely contain rifampin or rifampin derivatives. Rifampin's primary disadvantage is its potent inductive capability. Rifapentine, a cyclo-pentyl cogener of rifampin was developed to overcome this shortcoming. In vitroand murine studies show rifapentine to be a more potent killer than rifampin. Inaddition, rifapentine possesses a much longer half-life (approximately sixteen hours), which could allow for greater intermittent dosing to facilitate compliance while not foregoing efficacy. Rifapentine's ability to induce enzymes is only slightly less than rifampin's, however, leading to similar drug interactions. While rifampin's interactionsare well documented, rifapentine's require confirmation, especially with medications used to treat HIV, a common co-morbid condition in many countries.
General Note:
In the series University of Florida Digital Collections.
General Note:
Includes vita.
Bibliography:
Includes bibliographical references.
Source of Description:
Description based on online resource; title from PDF title page.
Source of Description:
This bibliographic record is available under the Creative Commons CC0 public domain dedication. The University of Florida Libraries, as creator of this bibliographic record, has waived all rights to it worldwide under copyright law, including all related and neighboring rights, to the extent allowed by law.
Statement of Responsibility:
by Eric Free Egelund.
Thesis:
Thesis (Ph.D.)--University of Florida, 2014.
Local:
Adviser: PELOQUIN,CHARLES A.
Local:
Co-adviser: PALMIERI,ANTHONY,III.
Electronic Access:
RESTRICTED TO UF STUDENTS, STAFF, FACULTY, AND ON-CAMPUS USE UNTIL 2015-05-31

Record Information

Source Institution:
UFRGP
Rights Management:
Applicable rights reserved.
Classification:
lcc - LD1780 2014
System ID:
UFE0046557:00001